Abiomed, Inc.
ABMD · NASDAQ
3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Revenue | $1,031,753 | $847,522 | $840,883 | $769,432 |
| % Growth | 21.7% | 0.8% | 9.3% | – |
| Cost of Goods Sold | $188,158 | $161,907 | $151,305 | $129,567 |
| Gross Profit | $843,595 | $685,615 | $689,578 | $639,865 |
| % Margin | 81.8% | 80.9% | 82% | 83.2% |
| R&D Expenses | $163,403 | $121,875 | $98,759 | $93,503 |
| G&A Expenses | $0 | $0 | $0 | $321,550 |
| SG&A Expenses | $423,486 | $334,183 | $341,600 | $321,550 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $586,889 | $456,058 | $440,359 | $415,053 |
| Operating Income | $372,692 | $229,557 | $249,219 | $224,812 |
| % Margin | 36.1% | 27.1% | 29.6% | 29.2% |
| Other Income/Exp. Net | -$182,132 | $58,663 | $7,606 | $38,548 |
| Pre-Tax Income | $190,560 | $288,220 | $256,825 | $263,360 |
| Tax Expense | $54,055 | $62,695 | $53,816 | $4,344 |
| Net Income | $136,505 | $225,525 | $203,009 | $259,016 |
| % Margin | 13.2% | 26.6% | 24.1% | 33.7% |
| EPS | 3 | 5 | 4.49 | 5.77 |
| % Growth | -40% | 11.4% | -22.2% | – |
| EPS Diluted | 2.98 | 4.94 | 4.43 | 5.61 |
| Weighted Avg Shares Out | 45,445 | 45,140 | 45,179 | 44,911 |
| Weighted Avg Shares Out Dil | 45,881 | 45,674 | 45,816 | 46,151 |
| Supplemental Information | – | – | – | – |
| Interest Income | $49,840 | $0 | $0 | $0 |
| Interest Expense | $49,840 | $0 | $0 | $0 |
| Depreciation & Amortization | $28,089 | $24,097 | $20,430 | $14,121 |
| EBITDA | $500,461 | $246,937 | $257,482 | $230,767 |
| % Margin | 48.5% | 29.1% | 30.6% | 30% |